NasdaqGS:DYNBiotechs
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data
Dyne Therapeutics (DYN) is back in focus after the company kicked off its Phase 3 HARMONIA trial for zeleciment basivarsen in myotonic dystrophy type 1, alongside fresh long term data from its Duchenne program.
See our latest analysis for Dyne Therapeutics.
Dyne Therapeutics’ recent HARMONIA Phase 3 launch and fresh DELIVER data arrive after a volatile stretch, with a 7 day share price return of 18.82% and a 1 year total shareholder return of 52.02%. This suggests momentum has recently picked...